Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275614 | 1.00 | AHCY (0.49) | AHCYADORA2BMETTL3PRMT5ALB | |
| SCHEMBL2803551 | 0.85 | AHCY (0.53) | AHCYADORA2BALB | |
| SCHEMBL11965625 | 0.85 | AHCY (0.53) | AHCYADORA2BALB | |
| SCHEMBL2803548 | 0.85 | AHCY (0.53) | AHCYADORA2BALB | |
| SCHEMBL9220438 | 0.84 | ALB (0.40) | AHCYALBADRB1DNMT1 | |
| SCHEMBL24839531 | 0.81 | TK1 (0.47) | AHCYALBADRB1DNMT1 | |
| SCHEMBL18018833 | 0.79 | METTL3 (0.31) | AHCYMETTL3PRMT5 | |
| SCHEMBL11496044 | 0.76 | LMNA (0.54) | AHCYADORA2BMETTL3PRMT5ALB | |
| SCHEMBL22765508 | 0.76 | AHCY (0.60) | AHCYADORA2BADRB1DNMT1 | |
| SCHEMBL17547612 | 0.76 | LMNA (0.54) | AHCYADORA2BMETTL3PRMT5ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| WO-2015051169-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | NSUN3, POLRMT, TRDMT1 | AHCY 2707/4885ADORA2B 1963/4885METTL3 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.